Pharmaceutical Executive-10-01-2012

Lundbeck's Big Bet

S

Pharm Exec takes a look at how a mid tier player - Denmark's Lundbeck - is counting on the momentum of the big US market to vault it to global leadership position.

A comparative effectiveness study on the two presidential candidates.

Pharmaceutical companies looking to wrest market share in high growth markets of tomorrow must overcome challenges from a new crop of national champions.

With respect to targeting, positioning, and launching new drugs, the ACA reform stands for Adjust, Change, and Adapt.

Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly-with a new product as the sum of its parts-depends on making that lengthy progression from basic science to registration as linear as possible.

The Brazilian government's policy on biologics doesn't adequately address non-biologic complex drugs. Additional guidance is needed to bring these important medicines to market.

In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East.

Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.

The new head of EFPIA faces a Promethean challenge: selling the merits of costly science and innovation in an era of bristling competition, fiscal crisis, and declining demographics.

With the costs of data storage poised to increase, pharmaceutical companies need to break their pack rat mentality with respect to data, writes Lorrie Luellig.